Research Analysts Offer Predictions for Nuvalent Q2 Earnings

Nuvalent, Inc. (NASDAQ:NUVL) – Research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for Nuvalent in a report released on Monday, November 17th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($1.48) per share for the quarter, down from their previous forecast of ($1.31). HC Wainwright has a “Buy” rating and a $155.00 price objective on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. HC Wainwright also issued estimates for Nuvalent’s Q3 2026 earnings at ($1.43) EPS, Q4 2026 earnings at ($1.19) EPS and FY2026 earnings at ($5.62) EPS.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same quarter last year, the company posted ($1.28) earnings per share.

NUVL has been the topic of a number of other reports. Robert W. Baird raised their price target on shares of Nuvalent from $112.00 to $158.00 and gave the stock an “outperform” rating in a research report on Tuesday. Guggenheim raised their target price on shares of Nuvalent from $125.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday. UBS Group upped their target price on Nuvalent from $114.00 to $132.00 and gave the company a “buy” rating in a report on Friday, October 31st. Barclays set a $152.00 price target on Nuvalent in a research report on Monday. Finally, Leerink Partners boosted their price objective on Nuvalent from $140.00 to $149.00 and gave the company an “outperform” rating in a research report on Monday. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $137.69.

Nuvalent Price Performance

Nuvalent stock opened at $108.01 on Wednesday. Nuvalent has a 12 month low of $55.53 and a 12 month high of $112.88. The company has a fifty day moving average price of $90.20 and a two-hundred day moving average price of $81.61. The company has a market cap of $7.85 billion, a PE ratio of -20.30 and a beta of 1.31.

Institutional Investors Weigh In On Nuvalent

A number of hedge funds and other institutional investors have recently modified their holdings of NUVL. Vanguard Group Inc. grew its position in Nuvalent by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 4,605,007 shares of the company’s stock valued at $398,241,000 after buying an additional 80,883 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Nuvalent by 46.0% during the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock worth $198,979,000 after buying an additional 724,491 shares in the last quarter. State Street Corp lifted its stake in shares of Nuvalent by 4.2% in the 2nd quarter. State Street Corp now owns 1,490,279 shares of the company’s stock worth $113,708,000 after acquiring an additional 59,620 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Nuvalent by 11.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,450,602 shares of the company’s stock valued at $102,878,000 after acquiring an additional 152,692 shares in the last quarter. Finally, Commodore Capital LP increased its stake in shares of Nuvalent by 1.8% during the third quarter. Commodore Capital LP now owns 1,400,000 shares of the company’s stock valued at $121,072,000 after acquiring an additional 25,000 shares during the period. 97.26% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Nuvalent news, insider Deborah Ann Miller sold 24,200 shares of Nuvalent stock in a transaction on Monday, November 17th. The stock was sold at an average price of $105.50, for a total transaction of $2,553,100.00. Following the sale, the insider owned 49,086 shares of the company’s stock, valued at $5,178,573. The trade was a 33.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James Richard Porter sold 27,000 shares of the stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $90.63, for a total value of $2,447,010.00. Following the completion of the transaction, the chief executive officer directly owned 249,062 shares of the company’s stock, valued at approximately $22,572,489.06. The trade was a 9.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 291,000 shares of company stock valued at $27,207,121. Corporate insiders own 10.20% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.